
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated positive efficacy in treating patients with endometrial cancer, as investor confidence grows towards the drug’s blockbuster future. Given as a monotherapy every three weeks, …